To identify serum biomarkers that allow monitoring of disease progression and treatment effects in Duchenne muscular dystrophy (DMD) patients, levels of matrix metalloproteinase-9 (MMP-9), tissue inhibitors of metalloproteinase-1 (TIMP-1) and osteopontin (OPN) were determined in 63 DMD patients on corticosteroid therapy. These proteins were selected for their role in the pathogenesis of muscular dystrophy. Levels of MMP-9 and TIMP-1 were significantly higher in sera of DMD patients compared to healthy controls, whereas the OPN levels showed no significant difference. MMP-9 levels were also observed to be significantly higher in older, nonambulant patients, compared to ambulant patients. Longitudinal data from a smaller cohort of DMD patients followed up for over 4 years showed that MMP-9, but not TIMP-1 increased significantly with age. Hence, MMP-9 is a potential DMD biomarker for disease progression. Future studies have to confirm whether serum MMP-9 levels can be used to monitor therapeutic response. Ó 2011 Elsevier B.V.
Introduction
Clinical biomarkers can be used to diagnose, monitor aetiology and progression of diseases and guide therapeutic decisions [1] . The serum biomarker currently used primarily as a first diagnostic hint for Duchenne muscular dystrophy (DMD), is creatine kinase (CK), where high levels of CK reflect muscle damage and/or disease. There are, however, several drawbacks to the CK test: levels may fall when disease progresses, probably due to the loss of muscle tissue [2] , and CK levels are also increased in normal individuals due to exercise, exertion or trauma to the skeletal muscle. Other available tests to monitor the progression of DMD pathology have limitations as well. Muscle biopsies have diagnostic value, but are laborious and invasive, and provide only local information on muscle quality, which may not be reflective for the state of all muscles. Muscle strength assessments are less of a burden to the patient and have prognostic applications, but are subject to extensive intra-and inter-patient variability [3] . As such, there is no single test that can be used for diagnosis, prognosis, the recognition and/or prediction of potential complications and response to treatment. However, it might be feasible to achieve this with a group of serum biomarkers. the various clinical treatments and trials currently ongoing for DMD [4] [5] [6] [7] , the identification of serum biomarkers to assess the effect of these treatments would be invaluable, since functional improvement cannot be expected within the short treatment periods in early phase clinical trials, and monitoring through repetitive muscle biopsies is not feasible for longer trials.
Based on recent literature findings on the pathophysiology of dystrophinopathy in both men and mice (dystrophin deficient mouse, mdx) via gene expression analyses [8] [9] [10] [11] , we selected several potential serum biomarkers for DMD: matrix metalloproteinase 9 (MMP-9), tissue inhibitor of metalloproteinase (TIMP-1) and osteopontin (OPN). MMP-9 is associated with the degradation or remodelling of the extracellular matrix and is either secreted or present as a trans-membrane proenzyme. It has recently been demonstrated that Mmp9 gene expression is increased in mdx mice and inhibition of Mmp9 reduces skeletal muscle damage, inflammation, necrosis and fibrosis [8] . This implies that the absence of MMP-9 in mdx mice reduces the effects of dystrophin deficiency in the skeletal muscle. The proteolytic activity of MMP-9 is modulated by TIMPs and it has been postulated that the maintenance of the balance between MMP-9 and TIMPs is essential to maintain tissue integrity [12] . Gene expression analysis of mdx and DMD muscles showed an upregulation of the TIMP1 gene [7, 8] suggesting it is worthwhile to include TIMP-1 in our biomarker study. OPN, a phosphorylated glycoprotein of the bone, is also expressed in immune cells, skin and blood vessels. The functions of OPN include formation of collagen fibrils during tissue remodelling, promotion of macrophage and neutrophil migration, angiogenesis and wound healing [11] . A recent study revealed that mdx mice have high OPN serum concentrations, while absence of the OPN encoding Spp1 gene in mice reduced neutrophils and decreased TGF-b levels resulting in reduced fibrosis in mdx mice [11] . Interestingly, studies on gene expression profiles of DMD muscles at various stages of the disease also demonstrated significant upregulation of SPP1 [9, [13] [14] [15] .
The three selected biomarkers are suggested to have a role either in inflammation, fibrosis, or extracellular matrix degradation, which are key events in the pathogenesis of DMD. We hypothesize that these biomarkers will be elevated in the DMD sera since DMD muscle fibres are leaky and continuously degenerating. Furthermore, as these markers are indicative for the disease pathophysiology, we suggest that they have potential as prognostic biomarkers. Our study examined serum levels of the selected biomarkers in mdx mice and in sera of corticosteroid treated DMD patients. The animal and patient studies reinforced each other, as mouse studies are better controlled but cannot be directly extrapolated to humans. Based on comparisons with control samples and correlations with other patient information, we suggest that MMP-9 and TIMP-1 in combination can be used as potential biomarkers for monitoring disease progression in DMD.
Methods

Mice
Four week old C57BL/10ScSnJ (wt) (N = 5) and C57BL/10ScSn-mdx/J (mdx) (N = 6) females were subjected to forced exercise consisting of three times a week horizontal treadmill running at 12 m/min for 30 min for duration of 12 weeks to augment the severity of disease [16] . Blood was collected at the age of 8 and 14 weeks via the tail vein, allowed to clot at room temperature for 10 min and then spun at 1700 g for 10 min at 4°C before pipetting the serum for storage at À80°C, prior to use. For CK determination blood from the tail vein was collected in a Minicollect tube (0.8 ml Lithium Heparin Sep, Greiner bio-one, Austria). All mice were sacrificed at the age of 16 weeks by cervical dislocation. The quadriceps muscle was isolated, snap frozen in isopenthane, cooled in liquid nitrogen and stored at À80°C. Quadriceps muscles from nonexercised mdx mice were used as controls for the gene expression studies. All experiments were approved by the Institutional Animal Experimental Commission (DEC) at LUMC.
Study participants
Sixty-three male patients with a molecular diagnosis of DMD were recruited for this study from the clinic population of the muscle service in Newcastle upon Tyne (mean age 13.1 years, age range between 2.9 and 31.2 years). As shown in Table 1 , 34 of the patients were ambulant, with a mean age of 8.7 years and 29 were nonambulant, with a mean age of 18.1 years. Other clinical information such as duration of corticosteroid therapy and North Star Ambulatory Assessment (NSAA) scores were also available for these patients. Patients were on corticosteroid therapy for an average of 3.2 years and the mean NSAA score (available only for 29 ambulant patients) was 23/34.
Nine of the boys were followed up in a longitudinal study involving blood sampling at various time intervals [17] . They were on corticosteroid therapy, commenced at a dose of 0.75 mg/kg/day of prednisolone as per international guidelines [18] . Child D8 was on deflazacort prior to and for the duration of the study due to unacceptable side effects from prednisolone ( Table 2 ). The characteristics of the nine boys are summarised in Table 2 , as the type of mutation, age of the boys, duration of corticosteroid treatment and the North Star Ambulatory Scores (NSAA) were also documented.
As part of the study four adult males (age range, 29.6-5.3 years; mean 32.4 years) and 12 healthy male children (age range, 6.25-1.9 years; mean 8.2 years) were recruited as controls. The healthy adult males (N = 4) were working at the Institute of Human Genetics when recruited. The control children were attending the Royal Victoria Infirmary, Newcastle upon Tyne for venepuncture for renal isotope imaging after a urinary tract infection. Any child with an abnormal renal isotope investigation was subsequently excluded from the study. Informed consent was taken from the parents after a further discussion of the study with both parents and child. The control children had no significant medical disorders and were not on any systemic medication. All elements of the human study received a favourable opinion from the local Research Ethics Committee prior to commencement.
Human serum samples
Blood was taken from DMD and control groups by the following method: 3-5 ml of venous blood (obtained prior to radioisotope injection for the child controls) was drawn and placed in BD-Vacutainer (367694) tubes. The blood was allowed to clot at room temperature for 10 min and then placed in a refrigerator at 4°C before further spinning at 2800 g at room temperature for 10 min. The serum supernatant was carefully removed and aliquoted for storage at À80°C pending use.
RNA isolation and RT-PCR analysis
Total RNA of the quadriceps was isolated in Magna Lyser Green Beads tubes (Roche diagnostics Ltd., UK) using RNA-Bee (Tel-Test, Bio-Connect, Huissen, The Netherlands) and purified with the NucleoSpin RNA II kit (Bioke, The Netherlands). The RNA concentration was measured on a Nanodrop (Nanodrop Technologies, DE, USA) and integrity was checked with a lab-on-chip 
Determination of MMP-9, TIMP-1 and OPN levels in mice and human serum samples
Levels of MMP-9, TIMP-1 and OPN were determined using commercially available immunoassays kits. To determine levels in mouse serum, the mouse MMP-9 (total) immunoassay kit (catalogue number MMPT90) and mouse TIMP-1 immunoassay (catalogue number MTM100) were purchased from R&D systems (Abingdon, United Kingdom), while the mouse OPN kit (code number 27351) was purchased from IBL (Hamburg, Germany). The immunoassay kits for detection in human serum were the Human MMP-9 (total) immunoassay kit (catalogue number DMP900), the Human TIMP-1 immunoassay kit (catalogue number DTM100) and the Human OPN immunoassay kit (catalogue number DOST00) all purchased from R&D systems. These kits used the quantitative sandwich enzyme immunoassay technique where only free, unbound forms of the biomarkers are detected. All experiments were carried out in duplicates using the manufacturer's instructions.
Statistical analysis
Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS), version 17. All data sets were subjected to normality testing using the Kolmogorov-Smirnov method. For comparisons between means the Student's t-test (two-tailed) was applied. Additionally, data on the independent study groups (DMD and controls) were presented using descriptive statistics in which the median value and interquartile range (IQR, the statistical dispersion of the middle 50% of the data) were calculated to show the distribution of the biomarker levels for each group. Pearson's Correlation was used for correlation studies and data were analysed with a 95% confidence interval and P < 0.05 was considered significant and P < 0.01 was considered highly significant. For the longitudinal DMD group, the statistical package from R2.9.2 was used and the linear mixed-effects model (lme4, version 0.999375-38) was applied to determine the relationship of each biomarker with age and duration of corticosteroid therapy. The fixed and random effects used in this model were as follows: for fixed it was age and duration of corticosteroid therapy and for random, it was the patient.
Results
Gene expression analysis of Mmp9, Timp1 and Spp1 in mouse quadriceps
As we had begun our study by selecting candidate biomarkers from mdx gene expression data, we first confirmed whether these mRNA expression changes were also present in the mice used in our study. Whereas previously reported studies on these biomarkers used sedentary mice [6, 9] , the mdx and wt mice used for serum collection were subject to exercise to augment the severity of the disease. We therefore compared the gene expression of Mmp9, Timp1 and Spp1 (coding for OPN) between the study mice groups (exercised mdx and exercised wt) and nonexercised mice (mdx) using qPCR analysis. Fig. 1a, b and c show the gene expression data of Mmp9, Timp1 and Spp1, respectively, from the quadriceps of 16 week old, exercised mdx and mdx compared to exercised wt. We observed no significant difference between the expression of these genes in the exercised mdx and mdx group. There was, however, a significant difference between exercised wt and mdx. Although gene expression in exercised mdx was much higher than in exercised wt mice, this difference was not significant due to a higher standard deviation (SD) observed in the exercised mdx group compared to the exercised wt and mdx group.
Mouse serum levels of MMP-9, TIMP-1 and OPN
We then assessed serum from 8 and 14 week old exercised mdx and exercised wt mice. At the age of 8 weeks, a highly significant difference was observed in the serum MMP-9 levels between exercised wt and exercised mdx mice. The serum MMP-9 levels in exercised mdx mice were twofold higher than in exercised wt mice, with mean levels of 41.8 ng/ml ± 10.5 (level ± SD) for exercised wt mice and 86.52 ng/ml ± 21.07 for exercised mdx mice (Fig. 2a) . At the age of 14 weeks, levels of MMP-9 were still elevated in exercised mdx mice (mean = 62.53 ng/ml ± 39.4), however this difference was not significant when compared to exercised wt mice at the similar age group (mean = 37.85 ng/ml ± 3.50). There were no significant differences in the serum levels at the different time points for either exercised wt or exercised mdx mice. However in exercised mdx mice, a drop in serum levels of MMP-9 was noted between 8 and 14 weeks.
The levels of TIMP-1 at 8 weeks were 3-fold higher in exercised mdx mice (mean = 6.9 ng/ml ± 1.32) compared to exercised wt mice (mean = 2.22 ng/ml ± 0.91), and this difference was significant (P < 0.01) (Fig. 2b) . Although a difference was observed in the TIMP-1 levels in 14 week old mice, where exercised mdx mice (mean = 7.25 ng/ ml ± 1.55) had higher levels than exercised wt mice (mean = 4.78 ng/ml ± 2.62), this difference was not significant. There was also no significant difference in the levels of TIMP-1 between 8 and 14 weeks for both strains.
Serum OPN levels were found to be higher (P < 0.05) in 8 week old exercised mdx mice (mean = 3.44 ng/ml ± 0.54) compared to exercised wt mice (mean = 2.62 ng/ml ± 0.59) (Fig. 2c) . At 14 weeks, the levels were similar for exercised mdx (mean = 2.53 ng/ml ± 0.73) and exercised wt mice (mean = 2.36 ng/ml ± 0.91).
CK levels were also determined for the 8 and 14 weeks groups (Fig. 2d ) and significant differences were observed between exercised wt and exercised mdx for mice at both age groups. At 8 weeks, the CK levels for exercised wt were lower (mean = 142 U/L ± 100) than the CK levels for exercised mdx (mean = 3900 U/L ± 1631). At 14 weeks, this difference is smaller but still significant as the CK levels for exercised wt were 230 U/L ± 102 whereas they were 4773U/L ± 4024 for exercised mdx.
3.3. Serum levels of MMP-9, TIMP-1, and OPN in DMD and control samples
We measured the serum levels of MMP-9, TIMP-1 and OPN in serum samples of 63 DMD boys and 16 control subjects (12 age-matched boys and 4 adult men) and statistically compared the levels with Students t-test. The 12 boys and 4 adults in the healthy control group were grouped together since there were no differences between biomarker levels in young and adult subjects (data not shown). As shown in Fig. 3a , serum MMP-9 levels were significantly higher in DMD (median level = 1185.34 ng/ ml, IQR = 966.56) compared to control samples (median level = 73.22 ng/ml, IQR = 121.00) (P < 0.001). Similarly, serum TIMP-1 (Fig. 3b ) levels were significantly higher in DMD (median levels = 245.55 ng/ml, IQR = 69.57) compared to control groups (median level = 164.77 ng/ml, IQR = 62.45) (P < 0.01). The serum OPN levels, however, were not significantly different between DMD (median levels = 41.24 ng/ml, IQR = 33.74) and control groups (median level = 44.19 ng/ml, IQR = 30.69) (Fig. 3c) .
Further stratification of the DMD samples into ambulant and nonambulant groups (Fig. 4) showed significantly higher levels for nonambulant compared to ambulant for MMP-9 (ambulant group median levels = 927.89, IQR = 885.60; nonambulant group median levels = 1328.45, IQR = 822.95), while both groups were significantly increased compared to the control group. By contrast, similar levels were observed in ambulant and nonambulant groups for TIMP-1, which were both significantly higher than in the control group (Fig. 4b) . OPN levels were similar for all three groups (Fig. 4c) .
Correlation between levels of MMP-9, TIMP-1, OPN, age, steroid treatment and NSAA scores in DMD and control groups
Pearson correlation analysis was applied to determine the correlation coefficient between the three biomarker levels with other patient characteristics (age, years on steroid treatment and NSAA scores) in the independent DMD patient cohort (as observed from Table 3 ). MMP-9 levels were positively correlated with age and duration of corticosteroid therapy (P < 0.01). There were however, no significant correlations observed between levels of MMP-9 and TIMP-1, OPN or the functional scores, NSAA (ambulant boys only). There was a significant positive correlation between age and duration of corticosteroid therapy (P < 0.05) and although there was negative correlation (correlation coefficient of À0.241) between age and the NSAA scores, the effect was not significant. Age dependent Fig. 1 . Gene expression analysis of (a) Mmp9, (b) Timp1 and (c) Spp1 in exercised wt, exercised mdx and mdx. The bar charts show the mean levels of gene expression for each biomarker and the error bars indicate the standard deviation. One way ANOVA was used to determine differences between groups and the Student's t-test was applied to determine significant differences between two groups, where P < 0.01 is considered highly significant, and P < 0.05 is significant. The number of mice per group is five for wt and six for mdx.
trends were not observed for TIMP-1 and OPN. Serum OPN showed negative correlation with NSAA scores (correlation coefficient of À0.309), however this effect was not significant. In the control group, no significant correlation was observed between any of the variables (age, serum MMP-9, TIMP-1 and OPN levels).
Longitudinal analysis of MMP-9, TIMP-1 and OPN in DMD patients
As nine patients were followed up longitudinally, there was an opportunity to determine serum levels of these biomarkers over time for the same group of patients. Fig. 4 shows the biomarker levels of the individual DMD patients followed up between two and four and a half years. The levels of MMP-9 (Fig. 5a ) increased with age whereas the levels of TIMP-1 (Fig. 5b) did not demonstrate a consistent increase with age. Interestingly, the levels of OPN (Fig. 5c ) seemed to decrease with age. To determine whether age and duration of corticosteroid therapy had an effect on biomarker levels, the linear mixed-effects model analysis was applied to the longitudinal data. We observed that MMP-9 shows a significant linear relationship with age (t-stat = 2.17, P < 0.01) but duration of corticosteroid therapy does not significantly contribute to this relationship (t-stat = 0.63, P = 0.53). OPN levels show a significant linear and negative relationship with age (t-stat = À2.77, P < 0.01) and the duration of corticosteroid therapy does not contribute significantly to this relationship (t-stat = 1.7, P = 0.1).
Discussion
The potential biomarkers explored in this study, were initially hinted at by recent findings in mdx mouse experiments. Gene expression analysis of mdx muscle showed that the Timp1 gene and the Spp1 gene (which encodes OPN) were significantly upregulated compared to muscles of healthy mice [10] , while other studies have shown that both MMP-9 and OPN were elevated in serum of the mdx mouse compared to wild-type [8, 11] . MMP-9, TIMP-1 and OPN are known to have a role as pro inflammatory markers [19, 20] and in the absence of dystrophin in mouse models, MMP-9 and OPN have been shown to have an effect in extra cellular matrix degeneration, inflammation and subsequent degeneration and regeneration of muscle fibres leading to fibrosis [8, 11] . Data from our 8 week old exercised mice confirmed the findings of these previous studies. TIMP-1 levels remained elevated in 14 week old exercised mdx mice, but MMP-9 and OPN levels appeared to decrease with age. These latter observations were not in agreement with previous reports [6, 9] , possibly as a consequence of the exercise regimen we used with our mdx mice. To examine whether our results differed because mice used in our study were subjected to forced exercise from the age Fig. 2 . Serum levels of (a) MMP-9, (b) TIMP-1, (c) OPN and (d) CK in exercised wt and exercised mdx at 8 and 14 weeks. The bar charts show the mean serum levels of each biomarker and the error bars indicate the standard deviation. One way ANOVA was used to determine differences between groups and the Student's t-test was applied to determine significant difference between two groups, where P < 0.01 is considered highly significant, and P < 0.05 is significant. The number of mice per group is five for wt and six for mdx.
of 4 weeks until time of blood sampling (8 weeks and 14 weeks) and sacrifice (16 weeks), we examined the gene expression of these three biomarkers in exercised mdx and nonexercised mdx mice. No significant differences in gene expression were observed between the exercised and One way ANOVA was used to determine differences between groups and the Student's t-test was applied to determine significant difference between two groups. nonexercised group for any of the biomarkers. We did however observe that inter mouse variation was higher in the exercised mdx group compared to the mdx and exercised wt. It has been suggested that the beneficial or deleterious effect of exercise on dystrophic muscles depends on the age of the animal at the start of exercise, the severity of pathology, the intensity, and the duration and type of training [21] . Although in this study these parameters were similar in the exercised mdx group, the severity of the dystrophy for each mouse may be more variable, which could contribute to the higher variation seen in this group.
Our results in humans are in line with the mouse data: levels of MMP-9 and TIMP-1 are higher in DMD compared to controls. We also observed that MMP-9 levels were significantly higher in older, nonambulant patients compared to the younger, ambulant patients, suggesting that there is an increase in MMP-9 levels with disease progression. Results of the longitudinal study supported this observation as levels of MMP-9 increased with age for individual patients. While this study reports on both MMP-9 and TIMP-1 levels in serum of DMD patients, gene expression analysis on DMD muscle tissue has indicated a role for elevated TIMP1 and MMP2 in extra cellular matrix modelling at early stages of disease development [9] , which makes it likely that MMP-9 and TIMP-1 are derived from dystrophic muscles. An earlier study to detect inflammatory proteins in muscles of symptomatic DMD patients (5-12 years) and pre-symptomatic patients (infants) showed that the transforming growth factor (TGF)-b pathway was activated in the symptomatic group [22] . The study by Li et al. 2009 suggested that MMP-9 increased TGF-beta levels, which in turn exacerbated muscle degeneration in dystrophic mice [8] . A recent study comparing plasma levels and muscle expression of TGF-b and TIMP-1 in DMD, congenital muscular dystrophy (CMD) and Becker muscular dystrophy (BMD) showed that these markers were markedly elevated in DMD and CMD compared to the less severe BMD [23] . Our data on serum levels of MMP-9 and TIMP-1 confirmed the findings of earlier studies on the pathogenesis of DMD.
The Pearson correlation analysis also confirmed a significant positive correlation between MMP-9 levels, age and duration of corticosteroid treatment in the 63 DMD patients. While the positive correlation between age and MMP-9 levels reflected the observation seen in the nonambulant and ambulant patients, the correlation between MMP-9 levels and duration of corticosteroid therapy needs further analysis. The patient cohort in our study was limited by the number of patients who were steroid naïve, and for patients that were on corticosteroid therapy, age and duration of treatment was confounded, making it difficult to discriminate between disease progression due to age and effects of steroid treatment. From the limited studies available on MMP-9 levels and corticosteroid therapy, one study on serum levels of patients with Graves ophthalmology and another on gene expression of MMP-9 in a murine model showed that MMP-9 levels were lowered after corticosteroid therapy [24, 25] while another study of asthmatic patients on corticosteroid therapy suggests that MMP-9 levels do not differ in steroid sensitive or resistant patients [26] . There was however one study which showed a short term increase in MMP-9 levels in patients with multiple sclerosis on a high dose of intra-venous methyl-prednisolone (1000 mg/day), where MMP-9 levels were noted to be significantly elevated at day 10 before returning to pre-treatment levels at day 20 [27] . In our study, the positive correlation between age and MMP-9 was further strengthened by the results of the linear mixed-effects analysis in the longitudinal DMD cohort as there was a significant and positive linear relationship between MMP-9 levels and age i.e. disease progression, and the duration of steroid treatment did not contribute significantly to this relationship. Thus, based on our findings and information available from the above mentioned literature, we suggest that elevated MMP-9 levels are due to disease progression rather than the effect of corticosteroid treatment.
Although we observed TIMP-1 levels to be significantly higher in DMD compared to controls, there was no significant difference in levels between ambulant and nonambulant groups or a significant correlation with age. However, due to the recent findings that plasma TIMP-1 levels are lower in less severe BMD compared to DMD [23] , the reports that ratio of MMP-9 and TIMP-1 reflected the balance of pro and anti-inflammatory cytokines [28] , and our own observation that TIMP-1 levels remained elevated in DMD patients, we suggest it is still useful to assess the potential of TIMP-1 as a biomarker in larger and independent cohorts from other clinical centres. OPN levels showed no significant difference between DMD and control samples or between ambulant and nonambulant groups. There was however a significant linear but negative relationship in the longitudinal cohort for OPN and age. A recent study on DMD patients with the less common G allele of the rs28357094 SPP1 promoter, which was associated to decreased OPN mRNA expression levels, suggested that less SPP1 leads to more muscle weakness, with lower grip strength and earlier age for loss of ambulance [14] . As serum OPN levels were not reported in that study, it would be of future interest to know whether blood OPN levels were lowered in the DMD patients carrying the less common G allele.
Current clinical trials on exon skipping and stop codon read-through [29] include CK as a serum biomarker to study the effectiveness of treatment. While decreasing CK levels can be a positive prognostic indicator in some diseases (myocardiac infarction for example), in DMD patients the role of CK as a prognostic biomarker is questionable. CK levels are markedly increased before signs and symptoms of DMD are observed, confirming the useful diagnostic application at a very early stage of the disease. However as mentioned earlier [2] , declining CK levels in DMD are associated to decrease in ambulatory skills and disease progression. We suggest that MMP-9 and TIMP-1 levels are potentially more useful biomarkers for response to therapy, since they do not show this decreasing trend, probably as a consequence of the continued inflammatory response in DMD patients, even after substantial muscle degeneration. Effective therapy should reduce the degeneration-induced inflammatory response. Future studies have to confirm whether MMP-9 and TIMP-1 indeed decrease after dystrophin restoration, and therefore are useful as biomarkers to monitor therapeutic responses.
Due to their role in inflammation, cell migration, angiogenesis and fibrosis [28, 30] , elevated levels of MMP-9 and TIMP-1 are not specific to DMD or muscle diseases. These markers have been investigated for their role in cancers (breast, bladder and pancreas), cardiovascular diseases and in preeclampsia. In breast cancer for example, MMP-9 is used as a marker for diagnosis and prognosis, early detection and risk assessment, but also as an indicator of tumour recurrence, metastatic spread, and response to primary and adjuvant therapy [28] . In coronary artery disease, the ratio of MMP-9/TIMP-1 in serum was suggested to be useful for progression of disease as it is reflective of the balance between circulating pro and anti inflammatory cytokines [30] . Hence, their diagnostic value for DMD per se may be limited. However, based on our study in mice and humans, we suggest to further evaluate MMP-9 and TIMP-1 as valuable biomarkers in DMD for the monitoring of disease progression and therapy efficacy. 
